Mirvetuximab Soravtansine: Delivering Powerful Results in Ovarian Cancer
Angeles Alvarez Secord, MD, MHSc, discusses key takeaways from the PICCOLO trial.
Mirvetuximab soravtansine (Elahere) is an antibody-drug conjugate designed to treat ovarian cancer. It works by binding to folate receptor-alpha (FRα). This binding delivers a potent anticancer drug to the tumor cells.
The PICCOLO trial (NCT05041257) was a phase 2 study that evaluated the effectiveness and safety of mirvetuximab soravtansine in patients with recurrent platinum-sensitive ovarian cancer. Patients in the trial had high levels of FRα expression and had received at least 2 prior lines of therapy.
In the study, mirvetuximab soravtansine demonstrated a significant response rate in patients, with over half achieving either a complete or partial response to treatment. The duration of response was also promising, with patients experiencing responses for an average of 8.3 months. While mirvetuximab soravtansine was generally well tolerated, some patients experienced side effects such as blurred vision and dry eye. These side effects were generally manageable.
Overall, the PICCOLO trial results suggest that mirvetuximb soravtansine is a promising treatment option for patients with recurrent platinum-sensitive ovarian cancer who have high levels of FRα expression.
Here, Angeles Alvarez Secord, MD, MHSc, gynecologic oncologist at Duke Cancer Center, discusses the key takeaways from the study presented at the 2024 ESMO Congress.
Transcription:
0:05 | I hope there are next steps, definitely. The findings from the study are very provocative and really promising in terms of the objective response rate and those individuals who've been heavily pretreated as well as been treated with a PARP inhibitor and progressed on a PARP inhibitor. In that group, the response rate was approximately 46%, which is higher than what we would have anticipated given some of the prior reports of diminished response in that group who gets treated with subsequent therapy. So I think the results are really exciting to explore further in that specific patient population, as well as providing an option for all of our patients who have heavily pretreated platinum-sensitive disease.
0:44 | It is incredibly important to get testing done on your patients. Understanding the level of the FRα expression will help you in terms of determining what is the next best treatment for them in order for them to have the highest chance of receiving benefit from a therapy, and it really helps me in terms of determining the sequence of therapy.
